44 Purpose: To evaluate relative diagnostic precision and test retest variability of two devices, 45 the Compass (CMP, CenterVue, Italy) fundus perimeter and the Humphrey Field Analyzer 46 (HFA, Zeiss, Dublin), in detecting glaucomatous optic neuropathy (GON). 47 Design: Multicentre cross-sectional case-control study. 48 Subjects: We sequentially enrolled 499 glaucoma patients and 444 normal subjects to analyse 49 relative precision. A separate group of 44 glaucoma patients and 54 normal subjects was 50 analysed to assess test -retest variability. 51 Methods: One eye of the recruited subjects was tested with the index tests: HFA (SITA 52
Conclusions: Relative diagnostic precision of the two devices is equivalent. Test-retest 70 variability of mean sensitivity for CMP was better than for HFA. 71 M A N U S C R I P T
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Standard Automated Perimetry (SAP) is used to assess the visual field (VF) and is a key 72 examination for detection, diagnosis and follow up in glaucoma. SAP typically uses stimuli of 73 varying intensities to assess the differential light sensitivity at static locations across the VF. 74
The examination demands strong cooperation 1 from test subjects; they are required to 75 maintain central fixation and respond timely and accurately to the presented stimuli. Fixation 76 instability might be an unavoidable feature of a person's vision, especially with advanced age 77 and macular damage 2 . One proposed solution has been to incorporate live fundus tracking in 78 the macular perimetric exam to compensate for eye movements in unstable fixation 3 . 79
Recently, a novel instrument, the COMPASS fundus perimeter (CMP, CenterVue, Padua, Italy), 80 has successfully employed a live fundus tracking technology for wide field (30 degrees) VF 81 assessment 4, 5 yielding results comparable with the Humphrey Field Analyzer (HFA) in a 82 preliminary study 4 . The CMP captures images of the fundus during the perimetric 83 examination using a scanning laser ophthalmoscope. This design feature is intended to afford 84 compensation for eye movements when the stimuli are presented at predetermined test 85 locations. Moreover, the instrument provides colour images of the fundus and optic nerve that 86 can be mapped to the final perimetric results potentially providing clinically useful 87 information about structure and function in one assessment. 88
Diagnostic accuracy studies are used to certify new examinations before they are brought into 89 clinical practice. The CMP has not yet been scrutinised in this way and this is the main 90 purpose of our investigation. Studies investigating relative diagnostic accuracy are at risk of 91 bias due to shortcomings in design and conduct. For this reason, we designed our study to 92 follow appropriate guidelines on this specific aim 6, 7 . 93
Our cross-sectional and multicentre study was designed to evaluate and compare two index 94 tests, namely the CMP and the HFA. One objective was to evaluate and compare test -retest M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT neuropathy (GON). We hypothesised that the CMP could obtain a 20% reduction in test-retest 97 variability on the measurement of the Mean Sensitivity (MS) of the VF. Another objective was 98 to build a normative database for the CMP and analyse its relative discriminative ability, 99 compared to HFA, in detecting subjects with GON. We specifically hypothesised that the two 100 index tests will have equivalent relative diagnostic precision as assessed by partial area under 101 the receiver operating characteristic (ROC) curve at >75% specificity, across a spectrum of 102 disease severity. In both analyses, the reference assessment for GON was specialist evaluation 103 based on the inspection of fundus photograph or Spectral Domain -Optical Coherence 104 Tomography (SD-OCT) evaluation of the Retinal Nerve Fibre Layer (RNFL), independent of 105 the VF. A further objective was to evaluate examination times for the CMP and HFA. 106 planned before the index test and reference standard were performed. The study was 118 designed to achieve a target number of 1000 glaucoma subjects and 600 healthy subjects for 119 the normative database and discrimination analysis. However, these targets were not reached 120 by the termination date of the study. 121
Participants eligible for inclusion were consecutive adults (18-90 years) with: 122 Eligible healthy participants were identified among staff in the clinics, volunteer registries, 147 patients' spouses or partners and patients attending the clinic for reasons other than 148 glaucoma (for example, for preoperative assessment for cataract in the fellow eye). 149
If deemed eligible for the study, healthy subjects were recruited consecutively. All analyses were based exclusively on the 52 locations in common between the 24-2 grid 185 (HFA) and the New Grid (CMP). 186
Differences between the two devices in terms of Mean Sensitivity (MS) and its decrease with 187 age in healthy subjects were analysed. Since the same eyes were tested with both devices, a 188 mixed model was used to account for repeated measurements. Normative lower limits for each location were calculated for TD values using quantile 198 regression 11, 12 to account for changes in normal variability with age. Since the variability of 199 thresholds in healthy subjects is known to increase with age 12, 13 , we only allowed for 200 negative slopes in quantile regression, meaning that normative limits could not shrink with 201 age. Only the lower 5% and 1% limits for TD values were used in this analysis. 202
For a fair comparison, TD values and their normative limits were calculated in the same 203 fashion for HFA and CMP, using the dataset of healthy subjects acquired with each respective 204 device in this study.
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For each VF, we calculated the total number of TD values below the 5% and 1% limits, which 206 we refer to as TD 5% and TD 1% respectively. 207
Discrimination ability of the two index tests was measured using MD, TD 5% and TD 1% as 208 classifiers. These classifiers were used to build Receiver Operating Characteristics (ROC) 209 curves. Instead of comparing the whole ROC curve, we analysed the Partial ROC curve (pROC) 210 down to a minimum specificity of 0.75 to avoid comparing the two devices at too low 211 specificity values that would fall far outside a clinically useful range. The 95% confidence 212 intervals for Partial Areas Under the Curves (pAUCs) and p-values for differences were 213 calculated via bootstrapping 14 . 214
The normative data, used to calculate MD and TD metrics and their normative limits, was 215 composed of the same set of healthy subjects used in the discrimination analysis to calculate 216 pROC curves and their pAUCs. Therefore, they are only used here to compare the relative 217 performance of the two devices and not to estimate or report their actual discriminative 218
power. 219
To compare test times, CMP average time per location was calculated for each test and the 220 result multiplied by the number of total points in a 24-2 grid (54 points). This made it 221 comparable with the testing time read from the printout of the HFA. System 2 (GSS2) 17 stage distribution for glaucoma participants is reported in Table 1 and 260 depicted in Figure 1 . 261
Subjects' age distributions are reported in Table 1 . Mean age (± standard deviation [SD]) was 262 48 ± 16 and 68 ± 11 years for the normal and glaucoma group respectively. 263
Average MS was lower with CMP compared to HFA in healthy subjects (Mean ± SD, 27.6 ± 1.6 264 dB vs 29.4 ± 2.0 dB) and glaucoma subjects (20.5 ± 6.7 dB vs 21.9 ± 6.9 dB) and these 265 differences were both statistically significant (p < 0.001). Comparison of the MD values in 266 healthy subjects has not been performed since this group was used to calculate the normative 267 average and therefore they were bound to have zero means for both devices. The MD values 268 from the two devices showed good agreement ( Figure 2) . Indeed, the average MD (± SD) for 269 glaucoma subjects was -6.55 ± 6.60 dB (Median: -4.37 dB, IQR: 8.92 dB) with CMP and -6.50 ± M A N U S C R I P T
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Average number of presentations (± SD) per location in CMP was 3.02 ± 0.55 for healthy 273 subjects and 3.70 ± 1.09 for glaucoma patients. Corrected test duration for CMP and test 274 duration for HFA were similar in both the healthy and glaucoma subjects (see Table 2 ). 275
Point-wise sensitivity was generally lower for CMP compared to HFA (Figure 3) . The average 276 mean difference was 1.85 ± 0.06 dB (Mean ± Standard Error, p < 0.001) in healthy subjects 277 and 1.46 ± 0.05 dB (Mean ± Standard Error, p < 0.001) in patients with glaucoma. Similarly to 278 the MD, such a difference was reduced when total deviations were considered in glaucoma 279 subjects (Figure 4 ), with 7 locations exceeding 1 dB difference. 280
The MS in the healthy group decreased with age in a similar fashion for both devices, with a 281 small but statistically significant difference (-0.051 ± 0.005 dB/year for HFA and -0.027 ± 282 0.005 dB/year for CMP; Mean ± Standard Error; p < 0.001 for slope difference). 283
The rate of false positives was 1.6 ± 4.0 % for CMP and 1.6 ± 2.3 % for HFA (Mean ± SD). 284 285 Discrimination analysis 286 Relative discriminative power (relative diagnostic precision) was marginally greater for CMP 287 when compared to HFA using the MD metric (pAUC difference ± Standard Error, 0.019 ± 288 0.009, p = 0.035, see Figure 5 ). There was no statistically significant difference in pAUC 289 between CMP and HFA when using TD 5% (p =0.18) or TD 1% (p=0.22) as the classifier. 290 Sensitivity values at selected specificities are reported in Table 3 . 291 292 Test -retest variability 293 By the end of the study, 99 subjects were screened; one subject did not complete all the 294 examinations and was excluded. In total 54 healthy subjects and 44 glaucoma patients, were 295 recruited for the test -retest study. Bland -Altman plots are reported in Figure 6 . The mean 296 difference in MS between the first and the second test with the CMP was statistically different The 95% limits of agreement for MS are depicted in Figure 6 . They were 49% (95% CIs: 17% 301 to 67%) narrower for CMP (Limits of agreement: -1.31, 1.63 dB) compared to HFA (Limits of 302 agreement: -2.84, 2.91 dB) in the healthy subjects. The 95% limits of agreement were 13% 303 narrower for CMP (Limits of agreement: -2.26, 3.14 dB) compared to HFA (Limits of 304 agreement: -3.11, 3.11 dB) in the glaucoma patients but the confidence intervals for these 305 estimates were very large (95% CI: -28% to 42%). In glaucoma subjects, the mean test -306 retest difference (± SD) was 0.44 ± 1.38 dB for CMP and 0 ± 1.59 dB for HFA. Bland -Altman 307 plots for all sensitivities are reported in Figure 7 . The 95% limits of agreement were generally 308 narrower for CMP for sensitivities above or equal to 15 dB (Mean Difference: 1.80 dB, 309 between 15 and 30 dB) and larger below 15 dB (Mean Difference: 5.46 dB). 310
Pointwise test -retest variability, calculated using the MAD was not significantly different 311 between CMP and HFA for glaucoma patients (Mean ± SD, CMP: 1.03 ± 1.01 dB, HFA: 1.07 ± 312 1.16 dB; Mean Difference ± SE, 0.03 ± 0.2 dB, p = 0.88) and for healthy subjects (Mean ± SD, 313 CMP: 0.59 ± 0.48 dB, HFA: 0.90 ± 1.15 dB; 0.08 ± 0.16 dB, p = 0.62). 314
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Discussion
316
This study was designed to compare two index tests, CMP and HFA, in terms of test -retest 317 variability and relative discriminative power. We recruited a large cohort of 943 subjects (499 318 patients with glaucoma and 444 healthy subjects) for the discrimination analysis and 98 319 subjects (44 glaucomatous and 54 healthy) to compare test-retest variability. The reference 320 standard used for the diagnosis of GON was independent of VF assessment, based on 321 specialist assessment of ONH colour photography and/or peripapillary RNFL thickness 322 measured with SD-OCT. 323
The primary objective was to show a reduction of test -retest variability in the MS of at least 324 20%. Such a reduction was achieved in healthy subjects (49%), but not in glaucoma subjects, 325
where the reduction was of 13%. Several factors might have contributed to this result, such as 326 a more pronounced perimetric learning effect with CMP 18-21 . The mean difference in MS in 327 CMP between the first and the second test was small but statistically significant and this may 328 be indicative of a learning effect in the glaucoma test -retest cohort. This effect was not seen 329 in the HFA data. Indeed, despite all glaucoma subjects in our sample having had previous 330 experience with SAP, the new setup of a fundus perimeter might have created an unfamiliar 331 testing condition for test takers. In fact, most of them were recruited from glaucoma clinics 332 and were experienced with HFA. The different threshold acquisition strategies employed by 333 the two devices may also explain this difference. SITA strategies incorporate spatial 334 information between neighbouring test locations. Such an approach allows for faster 335 threshold estimation, but it has been shown to bias the estimates introducing correlations 336 between neighbouring points 22, 23 . On the other hand, the implementation of the ZEST 337 strategy used in CMP tests each point independently. Moreover, test -retest variability is 338 known to increase dramatically at lower sensitivities [24] [25] [26] [27] and this effect may simply consume 339 any improvements from adjusting for fixation stability afforded by the tracking in fundus M A N U S C R I P T
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perimetry. We speculate this is the reason we see much bigger improvement in test-retest 341 variability in the healthy subjects compared to the patients in this study. This is supported by 342 the results shown in the Bland-Altman plots for pointwise sensitivities, where it can be 343 observed that the CMP offers no advantage in test-retest variability compared to HFA at 344 values below 15 dB. Indeed, the 95% limits of agreement between 11 and 14 dB were larger 345 for CMP than for HFA. The difference here might be explained by the spatial smoothing and 346 the use of growth pattern to seed the priors 9, 22 in the SITA strategy, which might play a large 347 role in reducing the test retest variability in this sensitivity range. However, the clinical utility 348 of thresholds below 15 dB has been questioned. Indeed, recent evidence suggests that 349 increasing perimetric contrast all the way to 0 dB may not be clinically useful and sensitivities performed with a 10-2 grid, which has a much finer spacing between locations (2 degrees). 359
Hence, further investigation is needed to assess the effect of gaze instability in the estimation 360 of edges on a typical testing grid, such as 24-2 or 30-2. 361
One limitation of our analysis is that the sample size of the glaucoma test -retest group was 362 probably too small to reliably assess any differences, as shown by the large confidence 363 intervals calculated via bootstrapping ( Supplementary Figure 2 , available at M A N U S C R I P T
that 97 glaucoma subjects would have been needed to detect a 20% improvement at a 366 significance level of 0.05 with 80% power. This is considerably above the initial estimates 367 obtained from literature data 15, 16 used for designing of the study. Therefore, an additional 368 investigation with longer test series on a larger sample might be needed to fully assess the 369 effect of fundus tracking on test -retest variability. 370
Relative discriminative power for the two index tests (devices) was similar. When compared, 371 pROC curves calculated using the number of abnormal points per field in the TD maps largely 372 overlapped, with no evidence for any superiority of either index test ( Figure 5 ). Statistically 373 significant differences in pROC curves were observed when MD was used as a classifier but 374 such differences are too small to be likely relevant in clinical situations. These results are 375 compatible with the fact that, although the actual sensitivity estimates were lower for CMP 376 compared to HFA, relative indices, such as the MD and TD values, showed only small 377 differences in glaucoma subjects between the two devices, yielding similar diagnostic ability. 378
Our results are based on a large sample of individuals from different centres. The different age 379 clusters, except for people older than 80 years of age, were well represented (Table 1) . This 380 was sufficient to reliably conduct an analysis on relative discriminative power. It is important 381 to note that, for both devices, all indices used in the discrimination analysis (MD, TD 5% and 382 TD 1%) and the normative limits for TD were recalculated in the same fashion from the raw 383 sensitivities and are therefore comparable. However, since the normative limits have been 384 derived from the same group of healthy subjects used in the discrimination analysis, the 385 pAUCs are biased and can only be used to compare the relative discriminative ability of the 386 two devices; they cannot be generalised to estimate the effective discriminative power of 387 either the CMP or the HFA in clinical practice. 388
Examination times for the two devices were similar. Both devices took, on average, 5 to 6 389 minutes to complete. Testing times had to be corrected prior to comparison due to the greater M A N U S C R I P T
number of tested locations with the New Grid used with CMP (65 locations) compared to the 391 HFA 24-2 grid (54 locations). After corrections, no statistically significant differences could be 392 detected between the two devices in healthy subjects. A statistical difference was observed in 393 glaucoma subjects but it is clinically irrelevant (approximately an 11 second difference on 394 average). Despite similarities in overall examination times, fewer presentations were needed 395 to estimate thresholds in CMP when compared to HFA at the 52 matching locations. The 396 number of presentations in healthy subjects was 157 ± 28, which is lower than that reported 397 for SITA-Standard in the literature (276 for 52 locations) 13 . Unfortunately, interpretation of 398 the examination times of the two devices is difficult for a variety of reasons. For example, CMP 399 uses catch trials whereas HFA SITA algorithms use response times to estimate false positive 400 error rates 31 . Moreover, the CMP does not project stimuli when the quality in the tracking 401 signal is low, and this may increase overall examination time. 402
One limitation of our study is that the glaucoma subjects were not stratified according to 403 disease severity, since VF data were not used in the diagnosis of GON. This could have 404 resulted in an uneven representation of glaucoma stages. However, the range of visual field 405 damage was sufficiently large to allow for a reliable evaluation across the whole spectrum of 406 glaucoma damage (see Table 1 and Figure 1) . 407
Our recruitment of healthy subjects was not population based and this is another potential 408 limitation of our study. The main design bias potentially recruiting 'super-normals' in studies 409 of diagnostic precision is to recruit the healthy control group using restriction criteria related 410 to the outcome of interest 32 , for example requiring the healthy controls to have normal visual 411 fields. We explicitly avoided this bias. Nevertheless, volunteers to clinical studies may be 412 healthier than an unselected population. This is very hard to avoid, because participants need 413 to volunteer. However, when we analysed the MD values from the HFA printouts of the 444 M A N U S C R I P T
built in the device, we found that our sample did not show important deviations from the 416 normative values. Indeed, the average MD was -1.12 ± 1.64 dB (Median: -0.91 dB, IQR: 1.97 417 dB). 418
Finally, the design of this study only allowed for a relative comparison of discriminative 419 power. Evaluation of the actual diagnostic accuracy would need a further validation on an 420 independent dataset, to assess how much these findings can be extracted on the general 421 population. Furthermore, such an evaluation should be conducted on a set of subjects before 422 the reference test (the clinical diagnosis of GON) is performed, as case-control scenarios are 423 known to produce biased estimates in discrimination analyses. One option might be to test 424 glaucoma suspects with the CMP before they are diagnosed as healthy or as having glaucoma. Compass had smaller test-retest variability than Humphrey Field Analyzer, both in normal 1 (49% reduction) and in glaucoma subjects (13% reduction). Compass had generally lower 2 threshold values, but Mean Deviation and Total Deviation values were interchangeable. 3
